Literature DB >> 20578837

Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.

Shu Xia1, Yin Zhao, Shiying Yu, Mengxian Zhang.   

Abstract

Activation of Akt, or protein kinase B, is frequently observed in human cancers. It has been demonstrated that PI3K activation leads to radiation resistance. Here, the role of PI3K/Akt/COX-2 pathway in the resistance to radiation in human cervical cancer HeLa cells is explored. Cultured HeLa cells were randomly assigned to five treatment groups: control, radiation, LY294002, PI3K antagonist, and the COX-2-antagonist celecoxib, with the objective of determining the role of PI3K/Akt/COX-2 pathway in the radiation resistance of HeLa cells. The cell survival ratios were computed by clone formation. To calculate the quasi-threshold dose (Dq), mean lethal dose (D(0)), survival fraction at 2 Gy radiation dose (SF(2)), and radiosensitization ratio, the cell survival curves were fitted to the one-hit multitarget model. The protein expression profiles for pAkt, Akt, COX-2, Bad, and pBad were detected by Western blot analysis, and the mRNA expression profiles for COX-2 and Bad were analyzed by RT-polymerase chain reaction. Treatment with a combination of celecoxib, LY294002, and radiation resulted in elevated Dq, D(0), and SF(2), and increased radiosensitivity in HeLa cells. The PI3K/Akt/COX-2 pathway was activated by radiation, whereas celecoxib inhibited the activation of the PI3K/Akt/COX-2 axis through several targets. Our results indicate that the activated PI3K/Akt/COX-2 signal transduction pathway was the main cause for decline in radiosensitivity in HeLa cells. This study proposes that the inhibition of the PI3K/Akt/COX-2 pathway can synergistically enhance radiation efficacy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578837     DOI: 10.1089/cbr.2009.0707

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  30 in total

1.  Effect of photodynamic therapy combined with Celecoxib on expression of cyclooxygenase-2 protein in HeLa cells.

Authors:  Yuanfu Mao; Lishuang Wang; Chen Xu; Shiyu Han
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

2.  Improved antitumor effect of ionizing radiation in combination with rapamycin for treating nasopharyngeal carcinoma.

Authors:  Di Wang; Lichen Gao; Xueting Liu; Chuang Yuan; Guihua Wang
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

Review 3.  Novel agents and treatment techniques to enhance radiotherapeutic outcomes in carcinoma of the uterine cervix.

Authors:  Ajeet Kumar Gandhi
Journal:  Ann Transl Med       Date:  2016-02

4.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Authors:  Linda S Steelman; Patrick Navolanic; William H Chappell; Stephen L Abrams; Ellis W T Wong; Alberto M Martelli; Lucio Cocco; Franca Stivala; Massimo Libra; Ferdinando Nicoletti; Lyudmyla B Drobot; Richard A Franklin; James A McCubrey
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

5.  Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma.

Authors:  Khin Than Win; Sung-Wei Lee; Hsuan-Ying Huang; Li-Ching Lin; Ching-Yih Lin; Chung-Hsi Hsing; Li-Tzong Chen; Chien-Feng Li
Journal:  Tumour Biol       Date:  2013-07-11

6.  Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.

Authors:  Sebastian Kuger; Dorothea Graus; Rico Brendtke; Nadine Günther; Astrid Katzer; Paul Lutyj; Bülent Polat; Manik Chatterjee; Vladimir L Sukhorukov; Michael Flentje; Cholpon S Djuzenova
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

7.  Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).

Authors:  Miho Iida; Kouji Banno; Megumi Yanokura; Kanako Nakamura; Masataka Adachi; Yuya Nogami; Kiyoko Umene; Kenta Masuda; Iori Kisu; Takashi Iwata; Kyoko Tanaka; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-06-23

8.  Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma.

Authors:  Ipsita Pal; Kaushik Kumar Dey; Madhuri Chaurasia; Sheetal Parida; Subhayan Das; Y Rajesh; Kulbhushan Sharma; Tamohan Chowdhury; Mahitosh Mandal
Journal:  Tumour Biol       Date:  2015-12-02

9.  Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Authors:  Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch
Journal:  Cancer       Date:  2013-08-23       Impact factor: 6.860

10.  The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.

Authors:  R Alex Harbison; Mark Kubik; Eric Q Konnick; Qing Zhang; Seok-Geun Lee; Heuijoon Park; Jianan Zhang; Christopher S Carlson; Chu Chen; Stephen M Schwartz; Cristina P Rodriguez; Umamaheswar Duvvuri; Eduardo Méndez
Journal:  JCI Insight       Date:  2018-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.